within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD03_MetforminAndRosiglitazone;

model MetforminAndRosiglitazone
  extends Pharmacolibrary.Drugs.ATC.A.A10BD03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BD03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Metformin and rosiglitazone is a fixed-dose combination oral medication used for the management of type 2 diabetes mellitus. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity, while rosiglitazone is a thiazolidinedione that enhances insulin sensitivity in peripheral tissues. The combination is approved for use in several countries to improve glycemic control in adults with type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in healthy adults and patients with type 2 diabetes. Parameters are reported from studies involving oral administration of the fixed-dose combination tablet (metformin 500 mg/rosiglitazone 2 mg) in adults.</p><h4>References</h4><ol><li><p>Chen, L, et al., &amp; Ma, A (2011). Simultaneous determination and pharmacokinetic study of metformin and rosiglitazone in human plasma by HPLC-ESI-MS. <i>Journal of chromatographic science</i> 49(2) 94–100. DOI:<a href=&quot;https://doi.org/10.1093/chrsci/49.2.94&quot;>10.1093/chrsci/49.2.94</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21223632/&quot;>https://pubmed.ncbi.nlm.nih.gov/21223632</a></p></li><li><p>Esteva, FJ, et al., &amp; Yeung, SC (2013). Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. <i>Cancer chemotherapy and pharmacology</i> 71(1) 63–72. DOI:<a href=&quot;https://doi.org/10.1007/s00280-012-1977-9&quot;>10.1007/s00280-012-1977-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23053261/&quot;>https://pubmed.ncbi.nlm.nih.gov/23053261</a></p></li><li><p>Molinuevo, MS, et al., &amp; Sedlinsky, C (2010). Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. <i>Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research</i> 25(2) 211–221. DOI:<a href=&quot;https://doi.org/10.1359/jbmr.090732&quot;>10.1359/jbmr.090732</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19594306/&quot;>https://pubmed.ncbi.nlm.nih.gov/19594306</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MetforminAndRosiglitazone;
